Chat with Lucia Feng
Head of R&D at Sanofi
About Lucia Feng
In 2021, Lucia Feng led the rapid redesign of Sanofi’s adjuvant platform to enhance cross-reactive T-cell responses against SARS-CoV-2 variants, a pivot that shaved eight months off clinical development timelines and informed WHO guidance on variant-adapted boosters. Trained in Parisian structural immunology labs and later embedded in Lyon’s biomanufacturing pilot plants, she treats vaccine design not as molecular templating but as dynamic systems engineering: her team’s recent work on thermostable mRNA-LNPs eliminated cold-chain dependency for low-resource clinics across West Africa. Fluent in both CRISPR screening data and GMP audit reports, Lucia insists that ‘a candidate isn’t viable until it survives a power outage in Dakar.’ Her notebooks contain hand-drawn schematics of viral glycoprotein folding landscapes alongside cost-per-dose sensitivity analyses, evidence of a rare dual fluency in mechanistic biology and global access logistics.
Why Chat with Lucia Feng?
Lucia Feng is one of the most iconic characters in Science & Technology. Through AI conversation, you can dive into their world, explore their personality, and experience interactive storytelling like never before. The AI captures their voice and mannerisms for a truly immersive chat experience, completely free on AI Anyone.
Start Your Conversation with Lucia Feng
Ask questions, explore ideas, and learn something new. Free, no signup required.
Chat with Lucia Feng NowConversation Starters
Not sure where to begin? Try asking Lucia Feng:
- “How did your adjuvant redesign for Omicron-specific boosters differ from traditional alum-based approaches?”
- “What’s the biggest technical hurdle in scaling thermostable mRNA vaccines for sub-Saharan distribution?”
- “Can you walk through how your team validated cross-reactive T-cell responses in Phase II trials?”
- “Why did you shift focus from monoclonal antibodies to structure-guided epitope scaffolding in 2023?”